Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- MSD’s Hep C Drugs Get Priority Review Status in Japan
April 20, 2016
- Biogen Files MS Treatment Dimethyl Fumarate in Japan
April 20, 2016
- FunPep, Morishita Jintan Sign MOU to Commercialize Products Containing Antibacterial Peptide
April 19, 2016
- AbbVie Starts Japan PIIb/III Study of Selective JAK1 Inhibitor in RA Patients
April 19, 2016
- Heptares, Kymab Tie Up for Joint Research on Cancer Immunotherapy
April 19, 2016
- Wholesalers Say Drug Distributions in Quake-Hit Kumamoto More or Less Stable
April 19, 2016
- Sanwa Kagaku’s Kumamoto Factory Shuts Down after Quake
April 18, 2016
- Kaketsuken Halts Operations on April 18-20 after Quake
April 18, 2016
- Announcement: 9th Annual eyeforpharma Japan 2016 - Westin Tokyo, July 13-14
April 15, 2016
- Sumitomo Dainippon, Kyoto Univ. Extend Cancer Research Collaboration
April 12, 2016
- MSD Picks Taiho as Copromotion Partner for Pembrolizumab
April 12, 2016
- Ono Fires Back to 1.75 Trillion Yen Guesstimate, Puts Opdivo Sales at 126 Billion Yen
April 12, 2016
- AC Medical to Introduce 3rd-Party Review Service for Advertising, Promotional Materials
April 12, 2016
- Companion Diagnostic for Tagrisso Now Covered by Health Insurance
April 11, 2016
- Ethical Drug Sales Jump 15.6% in February: Crecon Report
April 11, 2016
- Ex-Genzyme Japan Chief Hideyuki Ashikaga to Lead Baxter Japan
April 11, 2016
- Astellas Introduces 1st Major Reform of Domestic Marketing System in 10 Years to Understand Issues Specific to Each Area: Marketing Head
April 8, 2016
- Kaketsuken in Talks to Transfer Vaccine Biz to Astellas
April 8, 2016
- Bayer Japan Taps Big Data to Shorten Trial Site Selection by 1-2 Months; 2015 Sales Up 12.2%
April 7, 2016
- Takecab Most Promoted Drug in February: Anterio
April 7, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…